艾普拉唑
| 中文名称 | 艾普拉唑 |
|---|---|
| 中文同义词 | 艾普拉唑/奥普拉唑;艾普拉唑;奥普拉唑;艾普拉唑[干冰运输];伊拉普拉唑;替拉唑;2-(((4-甲氧基-3-甲基吡啶-2-基)甲基)亚砜基)-6-(1H-吡咯-1-基)-1H-苯并[D]咪唑;奥普拉唑标准品 |
| 英文名称 | Ilaprazole |
| 英文同义词 | 2-[(4-methoxy-3-methyl-pyridin-2-yl)methylsulfinyl]-5-pyrrol-1-yl-3H-benzoimidazole;2-[[(4-Methoxy-3-methyl-2-pyridinyl)methyl]sulfinyl]-6-(1H-pyrrol-1-yl)-1H-benzimidazole;IY 81149;1H-BenziMidazole,2-[[(4-Methoxy-3-Methyl-2-pyridinyl)Methyl]sulfinyl]-6-(1H-pyrrol-1-yl)-;2-[(4-methoxy-3-methylpyridin-2-yl)methylsulfinyl]-6-pyrrol-1-yl-1H-benzimidazole;IY81149; IY-81149; IY 81149;Ilaprazole USP/EP/BP;2-[(4-methoxy-3-methyl-pyridin-2-yl)methylsulfinyl]-5-pyrrol-1-yl-3H-benzoimidazole USP/EP/BP |
| CAS号 | 172152-36-2 |
| 分子式 | C19H18N4O2S |
| 分子量 | 366.44 |
| EINECS号 | 1308068-626-2 |
| 相关类别 | 医药中间体;医药原料;中药对照品;标准品;药物杂质及中间体;系列1;原料药;医药原料;试剂 |
| Mol文件 | 172152-36-2.mol |
| 结构式 |  |
艾普拉唑 性质
| 沸点 | 651.0±65.0 °C(Predicted) |
|---|---|
| 密度 | 1.39 |
| 储存条件 | Sealed in dry,Store in freezer, under -20°C |
| 溶解度 | DMF：10mg/mL；二甲基亚砜：15mg/mL； DMSO:PBS (pH 7.2) (1:7)：0.12mg/mL；乙醇：0.3mg/mL |
| 形态 | 固体 |
| 酸度系数(pKa) | 8.23±0.10(Predicted) |
| 颜色 | 米白色至灰色 |
| InChI | InChI=1S/C19H18N4O2S/c1-13-17(20-8-7-18(13)25-2)12-26(24)19-21-15-6-5-14(11-16(15)22-19)23-9-3-4-10-23/h3-11H,12H2,1-2H3,(H,21,22) |
| InChIKey | HRRXCXABAPSOCP-UHFFFAOYSA-N |
| SMILES | C1(S(CC2=NC=CC(OC)=C2C)=O)NC2=CC(N3C=CC=C3)=CC=C2N=1 |
艾普拉唑属不可逆型质子泵抑制剂，其结构属于苯并咪唑类。艾普拉唑经口服后 选择性地进入胃壁细胞，转化为次磺酰胺活性代谢物，与H + /K+ -ATP酶上的巯基作 用，形成二硫键的共价结合，不可逆抑制H + /K+ -ATP酶，产生抑制胃酸分泌的作用。
艾普拉唑目前主要用于胃糜烂、胃炎、反流性食管炎、消化性溃疡，以及幽门螺旋杆菌等感染。艾普拉唑的普遍副作用有（发病率超过1%、低于10%）有腹泻（2.41%）、头晕目眩（2.41%）、血细胞转氨酶（ALT/AST）上升（1.81%）；罕见副作用（发病率超过0.1%、低于1%）有皮疹、荨麻疹、腰痛、腹胀、口干口苦口臭、胸闷气短、心悸、月经时间增加、肾功能异常（蛋白尿、BUN上升）、心电图异常（室性期前收缩、I度房室传导阻滞）、白细胞减少等。所述副作用常以轻、轻中度，可自主修复。
Ilaprazole (IY-81149)是新型的质子泵 (proton pump)抑制剂，用于治疗消化不良、消化性溃疡、胃食管返流疾病和十二指肠溃疡。它能抑制H+/K+-ATPase，IC50为6 μM。| Target | Value |
|
Proton pump
() | |
|
H+/K+-ATPase
(Cell-free assay) | 6 μM |
|
TOPK
() | 111 μM(Kd) |
On cumulation of 14C-aminopyrine in histamine stimulated parietal cells, the IC 50 of Ilaprazole (IY-81149) sodium is 9 nM.
Ilaprazole (3-30 mg/kg; i.d.) dose-dependently inhibits gastric acid secretion.
In anesthetized rats, Ilaprazole dose-dependently increased gastric pH which was lowered by histamine infusion. In the case of i.v. injection, the ED
50
of Ilaprazole and omeprazole is 1.2 and 1.4 mg/kg and in the case of i.d. administration, the ED
50
of Ilaprazole and omeprazole is 3.9 and 4.1 mg/kg, respectively. Ilaprazole also significantly inhibits pentagastrin-stimulated gastric secretion. Its ED
50
is 2.1 mg/kg and that of Omeprazole is 3.5 mg/kg with i.d. administration. In the case of i.v. injection, Ilaprazole is equipotent to Omeprazole. Ilaprazole also inhibits gastric acid secretion strongly in fistular rats. The ED
50
of Ilaprazole administered intraduodenally is 0.43 mg/kg and that of Omeprazole is 0.68 mg/kg.
| Animal Model: | Male SD rat (after pylorus ligation) |
| Dosage: | 3, 10, 30 mg/kg |
| Administration: | Intraduodenally |
| Result: | The acid output and volume significantly inhibited by about 60 % and 46 % at 3 mg/kg were s, respectively. At 30 mg/kg, it showed 93 % and 73 % inhibition on acid output and volume, respectively. |